Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Trump Says Anthropic No Longer Seen as National Security Threat 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
SAN DIEGO, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Evofem, Inc. announces that Sandra Matsumoto has been named Vice President of Global Regulatory Affairs effective immediately. In this role, Dr. Matsumoto will be responsible for global regulatory strategy and lifecycle management of the Evofem product portfolio. She will report to Evofem Senior Vice President of Regulatory Affairs and Quality Assurance, Mary Jarosz.
"Sandra has extensive experience in the biotech and pharmaceutical industry," said Jarosz. "She has implemented global strategies from development to commercialization across several therapeutic areas and is a great addition to a well-established regulatory team."
Prior to joining Evofem, Dr. Matsumoto was the Senior Director of Global Regulatory Affairs for Vital Therapeutics, Inc., where she led biologics license application preparation for the treatment of severe liver disease. Before joining Vital, she held positions with increasing levels of responsibility in the areas of regulatory affairs, clinical development, and discovery research with several companies including Shire Regenerative Medicine and Illumina.
Dr. Matsumoto earned her PhD in Pharmacology and Toxicology from the University of Utah, her Master's of Science in Biology from California State University, Northridge and her Bachelor's of Science in Biology from UCLA. She also holds RAC certifications for the U.S. and E.U.
About Evofem
Evofem, Inc. is a late stage biotechnology company, headquartered in San Diego, CA, which focuses on the development and commercialization of women's reproductive health products, with a core focus on contraception.
Evofem, Inc. seeks to address a growing global contraceptive market, while delivering effective, woman-controlled products with global distribution. Evofem has two lead product candidates; Amphora, a non-hormonal contraceptive gel, and the Nestorone Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies.
For further information on the Company, please visit: www.evofem.com
CONTACT: Media Inquiries
Ellen Thomas
+1.718.490.3248
[email protected]
